20020079721

23 DEC 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08263 A3

(51) International Patent Classification[7]: C12N 15/86, 15/861, 15/864, 15/867, A61K 35/76

(21) International Application Number: PCT/GB01/03252

(22) International Filing Date: 19 July 2001 (19.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0017720.4 19 July 2000 (19.07.2000) GB

(71) Applicant *(for all designated States except US)*: **GOT-A-GENE AB** [SE/SE]; Stena Center 1B, S-412 92 Göteborg (SE).

(71) Applicant *(for GB only)*: **GARDNER, Rebecca** [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **LINDHOLM, Leif** [SE/SE]; Got-A-Gene AB, Stena Center 1B, S-412 92 Göteborg (SE). **NORD, Anna, Karin** [SE/SE]; Affibody AB, Björnnäsvägen 21, S-113 47 Stockholm (SE). **BOULANGER, Pierre, Alain** [FR/FR]; Faculté de Médecine RTH Laennec, Laboratoire de Virologie et Pathogénèse Virale CNRS UMR 5537, 7, rue Guillaume Paradin, F-69372 Lyon Cedex 8 (FR).

(74) Agents: **GARDNER, Rebecca** et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,

*[Continued on next page]*

(54) Title: MODIFIED VIRUS HAVING AN ALTERED TROPISM




(57) Abstract: The present invention describes a modified virus comprising one or more non-native polypeptides, which polypeptide comprises one or more framework moieties each containing one or more biding moieties, which polypeptides is capable of being expressed in the cytoplasm and nucleus of a mammalian host cell in a conformation which is maintained in the absence of a ligand for said binding moieties, said conformation allowing said binding moieties subsequently to bind with said ligand, and which polypeptide is capable of transport through the nuclear membrane, wherein said modified virus has an altered tropism conferred by said binding moieties and the use of such viruses in the therapy, particularly in the treatment of tumours or other cancerous cells.

*162162*

*ACTION*

WO 02/08263 A3